Impact of preoperative inflammatory and nutritional markers on the prognosis of patients with peritoneal metastasis of colorectal cancer

Table 2 Summary of demographics for patients treated with cytoreductive surgery according to the neutrophil-to-lymphocyte ratio/hemoglobin status

variables	NLR ≥ 3.1, n = 54	NLR < 3.1, n = 79	P value	Hb (normal), n = 94	Hb (low), n = 39	P value
Age (years), n (%)			0.531			0.017
≥ 60	31 (57.4)	41 (51.8)		39 (41.5)	25 (64.1)
< 60	23 (42.6)	38 (48.2)		55 (58.5)	14 (35.9)
Sex, n (%)			0.423			0.097
Male	34 (62.9)	55 (69.6)		67 (71.2)	22 (56.4)
Female	20 (37.1)	24 (30.4)		27 (28.7)	17 (43.6)
T category, n (%)			0.177			0.187
T0-3	24 (44.4)	26 (32.9)		43 (45.7)	13 (33.3)
T4	30 (55.6)	53 (67.1)		51 (54.2)	26 (66.7)
N category, n (%)			0.710			0.029
N0-1	29 (53.7)	45 (56.9)		58 (61.7)	16 (41.1)
N2	25 (46.3)	34 (43.1)		36 (38.2)	23 (58.9)
CRS, n (%)			0.014			0.001
CC 0/1	30 (55.6)	27 (34.1)		49 (52.1)	8 (20.5)
CC 2	24 (44.4)	52 (65.9)		45 (47.9)	31 (79.5)
HIPEC, n (%)			0.473			0.065
Yes	16 (29.6)	19 (24.1)		29 (30.8)	6 (15.3)
No	38 (70.4)	60 (75.9)		65 (69.2)	33 (84.7)
Albumin (g/L), n (%)			0.019			< 0.001
≥ 35	46 (85.1)	53 (67.1)		78 (82.9)	21 (53.9)
< 35	8 (14.8)	26 (32.9)		16 (17.1)	18 (46.1)
BMI (kg/m2), n (%)			0.907			0.985
≥ 18.5	44 (81.5)	65 (82.3)		77 (82.0)	32 (82.1)
< 18.5	10 (18.5)	14 (17.7)		17 (18.0)	7 (17.9)
Location of tumor, n (%)			0.320			0.319
Right side of the colon	16 (29.6)	30 (37.9)		35 (37.2)	11 (28.2)
Left side of the colon	38 (70.4)	49 (62.1)		59 (62.8)	28 (71.8)
PCI, n (%)			0.535			0.708
≥ 20	19 (35.1)	32 (40.5)		37 (39.3)	14 (35.8)
< 20	35 (64.8)	47 (59.5)		57 (60.7)	25 (64.2)
Histology, n (%)			0.305			0.572
Adenocarcinoma	45 (83.3)	60 (75.9)		73 (77.6)	32 (82.1)
Mucinous adenocarcinoma and signet-ring cell carcinoma	9 (16.6)	19 (24.1)		21 (22.4)	7 (17.9)

BMI: Body mass index; CRS: Cytoreductive surgery; HIPEC: Hyperthermic intraperitoneal chemotherapy; PCI: Peritoneal cancer index; NLR: Neutrophil-to-lymphocyte ratio; Hb: Hemoglobin.